Odyseey's OD-001 Meets Primary Goal In Ulcerative Colitis Study; Advances To Mid-Stage Trials

Odyssey Therapeutics reported that oral drug candidate OD-001 met the primary endpoint in a Phase 2a study of patients with moderate-to-severe ulcerative colitis, achieving a statistically significant improvement in disease activity. The provided article text cuts off after “12 we,” so the duration and any additional results are unavailable.